ArticleEmerging infectious diseases2020
Paradoxal Trends in Azole-Resistant Aspergillus fumigatus in a National Multicenter Surveillance Program, the Netherlands, 2013-2018.
Article in Emerging infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Aspergillus fumigatus-a systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial.Intensive care medicine · 2021Trial
- Ten-Year Voriconazole Susceptibility Trends Among 1482 ClinicalJournal of fungi (Basel, Switzerland) · 2026Article
- Amino acid substitutions at the G118 hotspot in dihydroorotate dehydrogenase confer olorofim resistance inMicrobiology spectrum · 2026Article
- Article
- Directed evolution of the pathogenic moldAntimicrobial agents and chemotherapy · 2026Article
- Climate change-driven geographical shifts iniScience · 2026Article
- Hospital Indoor Air as a Reservoir of Opportunistic Filamentous Fungi: Species Diversity and Antifungal Susceptibility.Current microbiology · 2026Article
- Understanding multi-azole resistance inFrontiers in fungal biology · 2026Article
- Current Evidence on Voriconazole Exposure and Individualized Therapy for Aspergillosis.Infection and drug resistance · 2026Review
- Contribution of the CYP51A Y119F Mutation to Azole Resistance inJournal of fungi (Basel, Switzerland) · 2025Article
- No Evidence for Environmental Triazole Resistance Selection Route in Aspergillus Section Flavi, The Netherlands, 1994-2023.Mycopathologia · 2025Article
- Antifungal resistance: Emerging mechanisms and implications (Review).Molecular medicine reports · 2025Review
- Evolution of antifungal resistance in the environment.Nature microbiology · 2025Review
- Article
- Epidemiology, antifungal susceptibility and biological characteristics of clinical Aspergillus fumigatus in a tertiary hospital.Scientific reports · 2025Article
- Is neutropenia still the main risk factor for invasive aspergillosis? A contemporary university hospital retrospective cohort of invasive aspergillosis in neutropenic and non-neutropenic patients.Annals of clinical microbiology and antimicrobials · 2025Observational
- Trends of Azole-Resistant Aspergillus Fumigatus Susceptibility Over 12 Years from a German ECMM Excellence Center.Mycopathologia · 2025Article
- Comprehensive Review of Environmental Surveillance for Azole-ResistantJournal of fungi (Basel, Switzerland) · 2025Review
- Land use drives drug resistance in an airborne human fungal pathogen.The ISME journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the prevalence of azole resistance of Aspergillus fumigatus isolates in the Netherlands by screening clinical A. fumigatus isolates for azole resistance during 2013-2018. We analyzed azole-resistant isolates phenotypically by in vitro susceptibility testing and for the presence of resistance mutations in the Cyp51A gene. Over the 6-year period, 508 (11%) of 4,496 culture-positive patients harbored an azole-resistant isolate. Resistance frequency increased from 7.6% (95% CI 5.9%-9.8%) in 2013 (58/760 patients) to 14.7% (95% CI 12.3%-17.4%) in 2018 (112/764 patients) (p = 0.0001). TR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.